Biovica International Should Double On Novel Breast Cancer Test Launch In Q3

  • Three months ago, I wrote an article for SA on Xbrane. I predicted a strong share price growth by the Phase 3 readout. Xbrane doubled.
  • Biovica is a similar case. It should double in the next three months. For the same reasons as Xbrane did.
  • Cancer diagnostics is a strongly evolving field. Biovica’s novel cancer test can detect breast cancer progress cheaper and much faster than current methods.
  • Its unprecedented 30 clinical trials in the prominent US and European hospitals minimize the risk of FDA failure. Biovica expects FDA approval and US launch by the Q3 end.
  • Share prices of pharma companies tend to move strongly before a major catalyst. Biovica should be a perfect example of this.

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Leave a Comment

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s